BACKGROUND:Mannitol, an osmotic diuretic, is proposed to be an oxygen radical scavenger. Mannitol is often used in renal transplantation to attenuate oxidative stress and thus to protect renal graft function. We tested the hypothesis that mannitol reduces overall oxidative stress during deceased donor renal transplantation. METHODS: We randomly assigned 34 patients undergoing deceased donor renal transplantation to receive asolution of mannitol or placebo shortly before graft reperfusion until the end of surgery. We evaluated oxidative stress by measuring the static oxidative-reduction potential (sORP) and the capacity of the oxidative-reduction potential (cORP). sORP and cORP were measured pre-operatively, before and within 10 minutes after graft reperfusion, and post-operatively. RESULTS:Seventeen patients were enrolled in the mannitol group and 17 patients were enrolled in the placebo group. Mannitol had no significant effect on sORP (148.5 mV [136.2; 160.2]) as compared to placebo (143.6 mV [135.8; 163.2], P = .99). There was also no significant difference in cORP between the mannitol (0.22 µC [0.16; 0.36]) and the placebo group (0.22 µC [0.17; 0.38], P = .76). CONCLUSION:Mannitol showed no systemic redox scavenging effects during deceased donor renal transplantation. To evaluate the direct effect of mannitol on the renal graft further studies are needed. TRIAL REGISTRATION: ClinicalTrials.gov NCT02705573.
RCT Entities:
BACKGROUND:Mannitol, an osmotic diuretic, is proposed to be an oxygen radical scavenger. Mannitol is often used in renal transplantation to attenuate oxidative stress and thus to protect renal graft function. We tested the hypothesis that mannitol reduces overall oxidative stress during deceased donor renal transplantation. METHODS: We randomly assigned 34 patients undergoing deceased donor renal transplantation to receive a solution of mannitol or placebo shortly before graft reperfusion until the end of surgery. We evaluated oxidative stress by measuring the static oxidative-reduction potential (sORP) and the capacity of the oxidative-reduction potential (cORP). sORP and cORP were measured pre-operatively, before and within 10 minutes after graft reperfusion, and post-operatively. RESULTS: Seventeen patients were enrolled in the mannitol group and 17 patients were enrolled in the placebo group. Mannitol had no significant effect on sORP (148.5 mV [136.2; 160.2]) as compared to placebo (143.6 mV [135.8; 163.2], P = .99). There was also no significant difference in cORP between the mannitol (0.22 µC [0.16; 0.36]) and the placebo group (0.22 µC [0.17; 0.38], P = .76). CONCLUSION:Mannitol showed no systemic redox scavenging effects during deceased donor renal transplantation. To evaluate the direct effect of mannitol on the renal graft further studies are needed. TRIAL REGISTRATION: ClinicalTrials.gov NCT02705573.
Authors: Vafi Salmasi; Kamal Maheshwari; Dongsheng Yang; Edward J Mascha; Asha Singh; Daniel I Sessler; Andrea Kurz Journal: Anesthesiology Date: 2017-01 Impact factor: 7.892
Authors: Despina N Perrea; Konstantinos G Moulakakis; Maria V Poulakou; Ioannis S Vlachos; Antonios Papachristodoulou; Alkiviadis I Kostakis Journal: Int Urol Nephrol Date: 2006 Impact factor: 2.370
Authors: A Feldheiser; V Pavlova; T Bonomo; A Jones; C Fotopoulou; J Sehouli; K-D Wernecke; C Spies Journal: Br J Anaesth Date: 2012-10-30 Impact factor: 9.166
Authors: Christoph Schwarz; Fabian Fitschek; David Bar-Or; Daniel A Klaus; Bianca Tudor; Edith Fleischmann; Georg Roth; Dietmar Tamandl; Thomas Wekerle; Michael Gnant; Martin Bodingbauer; Klaus Kaczirek Journal: PLoS One Date: 2017-10-18 Impact factor: 3.240
Authors: Christian Reiterer; Karin Hu; Samir Sljivic; Markus Falkner von Sonnenburg; Edith Fleischmann; Barbara Kabon Journal: Acta Anaesthesiol Scand Date: 2020-10-15 Impact factor: 2.105